SuanNutra and Myota unveil deal to deliver metabolic health solutions

SuanNutra reveals the company has entered into an exclusive distribution partnership with UK-based prebiotic innovator Myota to expand access to its clinically validated prebiotic fiber blends across the US, UK, and European markets. The partnership, which will officially launch at Vitafoods Europe 2025 in Barcelona, aims to address the growing global demand for microbiome-targeted metabolic health solutions.

At the center of the collaboration is Myota’s flagship product, Metabolic Regulator — a patented blend of nine plant-based fibers designed to modulate the gut microbiome and stimulate the production of short-chain fatty acids (SCFAs).

Ahead of the partnership’s launch, Nutrition Insight sits down with Jaime Duran, SuanNutra’s chief business officer, to learn the details of the partnership.

“We are primarily targeting health-conscious consumers of any case, from those concerned about their health in advance to those managing pre metabolic conditions,” says Duran. “Additionally, we see strong potential among individuals with digestive sensitivities, those seeking immune resilience, and consumers focused on holistic wellness.”

“The blends are also suited for segments interested in clean-label, science-backed formulations.”

Myota’s metabolic ingredient

Backed by research from the Massachusetts Institute of Technology in Cambridge, Massachusetts, US, and third-party clinical studies, Myota’s Metabolic Regulator formulation has demonstrated efficacy in improving blood sugar control, lowering cholesterol, and enhancing insulin sensitivity, particularly in individuals with metabolic syndrome.

This latest scientific synergy comes from combining Myota’s gut-focused innovation with SuanNutra’s Metabolaid, a botanically derived complex clinically shown to boost GLP-1 hormone levels, activate adenosine monophosphate-activated protein kinase (AMPK), and support healthy lipid and glucose metabolism.

Together, the two technologies offer a multi-layered approach to metabolic health — from gut microbiota modulation to cellular energy regulation.

“Myota’s blends stand out thanks to nearly a decade of proprietary research at MIT, clinical validation, and a unique formulation approach that combines a spectrum of fermentable fibers designed to stimulate SCFA production,” Duran explains.

“Unlike many generic prebiotics, Myota’s products are precision-formulated to address metabolic and digestive health, are low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs), and support personalized nutrition strategies.”The partnership expands the companies’ metabolic and gut-health solutions.

Expanding portfolios

In addition to Metabolic Regulator, SuanNutra will offer a full portfolio of Myota’s targeted blends for immune and digestive health. The prebiotics are formulated to be low-FODMAP and clean-label, making them suitable for individuals with digestive sensitivities.

The new product range will be showcased at Vitafoods Europe (May 20–22) at booth 3K22, where the companies will offer custom formulation support and explore further partnership opportunities.

“The partnership will initially focus on powder formulations as raw ingredients for dietary supplements of any type,” Duran reveals. “We will suggest to our customers, depending on their final formula, which kind of delivery format suits them best.”

“At this stage, the agreement covers the US, UK, and EU markets more broadly, without specific exclusions. Expansion into Germany and Austria is certainly a strategic consideration, but from now on, Myota will take care of them.”

Both companies state that this strategic alliance underscores the growing momentum behind microbiome-based health innovations and reflects their commitments to delivering next-generation solutions in the rapidly evolving nutraceutical space.

“This partnership directly supports SuanNutra’s long-term commitment to advancing clinically proven, microbiome-targeted solutions,” Duran concludes. “It enhances our existing portfolio, particularly in metabolic health, by offering new synergistic options alongside our flagship ingredients such as Metabolaid.”

“Our goal is to lead innovation in metabolic-health science by combining deep research, personalized nutrition, and scalable market access.”